Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study

YanLing He

Biomedical Research, Novartis, Cambridge, MA (Y.H., E.H., K.K., A.G.K., D.P.Y., C.J.O.).

Xueping Wu

Andre Serra-Roma

Biomedical Research, Novartis Pharma AG, Basel, Switzerland (A.S.-R., M.H., C.R.).

Maggie Markiewicz

Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.M., J.-H.Y.).

Emma Healy

Biomedical Research, Novartis, Cambridge, MA (Y.H., E.H., K.K., A.G.K., D.P.Y., C.J.O.).

Jing-He Yan

Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.M., J.-H.Y.).

Kenneth Kulmatycki

Biomedical Research, Novartis, Cambridge, MA (Y.H., E.H., K.K., A.G.K., D.P.Y., C.J.O.).

Tong Zhang

John L. Diener

Tectonic Therapeutic, Watertown, MA (J.L.D.).

Arvind G. Kinhikar

Biomedical Research, Novartis, Cambridge, MA (Y.H., E.H., K.K., A.G.K., D.P.Y., C.J.O.).

Denise P. Yates

Biomedical Research, Novartis, Cambridge, MA (Y.H., E.H., K.K., A.G.K., D.P.Y., C.J.O.).

David Nguyen

Markus Hinder

Biomedical Research, Novartis Pharma AG, Basel, Switzerland (A.S.-R., M.H., C.R.).

Cesare Russo

Biomedical Research, Novartis Pharma AG, Basel, Switzerland (A.S.-R., M.H., C.R.).

Christopher J. O’Donnell